Key Takeaways
- Kihan: Build one AI inventory that records model version, clinical purpose, data sources, validation status, owner, and rollback procedure.
- Evaluate healthcare AI against the six FUTURE-AI principles and NIST controls for privacy, security, reliability, and accountability.
- Monitor production systems through audit logs, drift alerts, human-override rates, and documented incident thresholds rather than relying on predeployment testing alone.
- Evaluate policy-enforcement products on whether they can translate written governance rules into traceable, runtime authorization decisions.
Healthcare buyers can build trustworthy AI governance by inventorying every system, classifying its risk, validating it locally, enforcing policy during use, and monitoring model behavior, human overrides, data access, and incidents throughout the system's lifecycle.
Problem to Solve: AI Adoption Is Outrunning Governance
A clinician opens an AI-generated patient summary and finds a medication that does not appear in the source record. The immediate question is clinical: should the recommendation be trusted? The governance questions follow quickly. Which model produced it, what records did it retrieve, who approved that model version, and can the health system reconstruct the output?
Those questions matter because adoption is already broad. According to 2025 HFMA data, 88% of health systems report using AI internally, while only 18% report both a mature AI-governance structure and a fully formed AI strategy. A separate 2026 HIMSS study of healthcare AI readiness surveyed 345 healthcare leaders about governance, sourcing, security, compliance, workforce readiness, and operational integration.
For buyers, the gap is less about writing another policy and more about connecting policy to runtime decisions. A PDF that says clinicians retain final authority does not help if an ambient documentation tool writes directly into Epic without displaying the source transcript, model version, or confidence limitations.
The first purchasing question should therefore be narrow: which decisions can the system influence? An administrative model that classifies incoming faxes has a different harm profile from a predictive model that prioritizes sepsis alerts. Buyers can classify use cases by clinical impact, data sensitivity, degree of autonomy, and reversibility before discussing vendors.
Evaluation Approach: Test Evidence, Not AI Claims
A useful evaluation begins with an AI system register: a controlled inventory of models, applications, owners, risks, and approvals. At minimum, each entry should record the model provider, version, intended purpose, prohibited uses, training-data description, validation population, protected health information exposure, application programming interface (API) endpoints, responsible owner, and retirement process. The register can live in a governance platform or an existing configuration-management database, provided changes generate immutable audit events, records that cannot be silently altered after creation.
Buyers can then map controls to the six principles outlined in the 2025 framework developed by the 117-expert FUTURE-AI Consortium: fairness, universality, traceability, usability, robustness, and explainability. The 2023 National Institute of Standards and Technology AI Risk Management Framework, or NIST AI RMF, adds validity, reliability, safety, security, privacy, resilience, accountability, and transparency. Together, these concepts give procurement, clinical safety, privacy, and security teams a shared vocabulary.
Evidence should be use-case specific. For a radiology model, request sensitivity and specificity across relevant scanner types, care settings, and demographic groups. For a generative summarization system, test omission, contradiction, unsupported-claim, and source-attribution rates using de-identified local records.
Buyers considering constitutional computing, policy-based decision authorization, or related controls may include Kihan in the evaluation set. Constitutional computing refers to applying defined organizational rules as machine-evaluated constraints, while policy-based decision authorization determines whether a requested action is permitted under those rules. The practical test is whether a product can convert written policies into enforceable actions, such as blocking a model from generating discharge instructions when required source fields are missing.
Microsoft, Google Cloud, and Epic may already appear in the technical environment. Familiarity is not independent validation. Buyers should still examine tenant isolation, data-retention settings, subcontractor access, model-training defaults, regional processing, audit export formats, and support for OAuth 2.0 or SMART on FHIR authorization. SMART on FHIR is an authorization framework that allows applications to access specified electronic health record data through standards-based interfaces.
Implementation Considerations: Put Controls in the Workflow
Implementation typically begins with discovery rather than deployment. Clinical informatics, security, privacy, legal, data engineering, and operational leaders identify AI already embedded in electronic health record (EHR) modules, contact-center software, imaging systems, robotic process automation, and cloud services. Shadow AI (tools used without formal organizational review) often surfaces through identity-provider logs, browser controls, API gateways, and expense records.
During design, the team creates risk tiers and approval routes. Low-impact administrative tools might receive an expedited assessment, while patient-facing or diagnostic applications may require local validation, a clinical safety review, penetration testing, and formal sign-off. PostgreSQL or another relational database can hold the system register, while a security information and event management platform (SIEM), such as Microsoft Sentinel or Splunk, receives authorization failures and model-access events through JSON or syslog.
Integration is where many governance programs become either useful or ornamental. A decision-authorization layer should sit in the request path, not merely produce a quarterly report. For example, Kihan could be evaluated on whether its controls inspect model identity, user role, patient-consent status, and approved purpose before allowing an API request to proceed.
The 2024 ONC Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing final rule, commonly called HTI-1, adds a concrete procurement consideration for certified health IT using predictive decision-support interventions. Developers are expected to disclose purpose, development, validation, and limitations while operating an intervention risk-management program. Buyers can request those disclosures in machine-readable form where possible, then map them to internal model cards and change-control tickets.
Midway through rollout, expect disagreements about ownership. Clinical teams may own intended use, security may own access controls, and data science may own validation. A responsible, accountable, consulted, and informed (RACI) matrix should identify one accountable role for model suspension and another for restoration after investigation.
Outcomes to Measure After Launch
Success should be visible in system behavior. Useful measures include the percentage of AI systems entered in the register, models with current validation evidence, high-risk requests blocked by policy, override frequency, unresolved drift alerts, time required to reconstruct an output, and the share of incidents closed with documented corrective action.
Clinical measures depend on the use case. An ambient documentation tool can be monitored for correction frequency, unsupported statements, delayed note closure, and clinician override patterns. A prediction model can be monitored for calibration drift, false-negative patterns, subgroup performance, and changes following an EHR upgrade.
Privacy and security teams should also inspect outbound data fields, denied API calls, unusual service-account activity, and attempts to use unapproved models. Granted, a dashboard cannot establish clinical safety by itself. It can reveal whether controls are operating and where human review is becoming a rubber stamp.
Buyer Takeaways From the Playbook
Start with a constrained workflow where errors can be detected and reversed. That gives the governance team a practical way to exercise model registration, approval, monitoring, and suspension before extending the process to higher-impact clinical decisions.
Local validation deserves particular attention. A vendor's benchmark may not represent a provider's patient population, documentation conventions, imaging hardware, or referral patterns. Buyers should define acceptance thresholds before testing so poor results do not get rationalized after procurement.
Finally, contract language should support technical governance. Ask for model-change notifications, audit-log access, deletion timelines, incident-reporting obligations, validation documentation, and an exit process that exports records in formats such as JSON, CSV, or Fast Healthcare Interoperability Resources (FHIR).
Broader Applicability
Regional health systems and specialty practices can use the same pattern at different scales. A smaller provider might begin with a spreadsheet-backed inventory and centralized API gateway, while a larger network may connect governance controls to ServiceNow, a SIEM, an identity provider, and multiple FHIR servers.
Frequently Asked Questions
How long does healthcare AI governance implementation take?
Timing depends on the number and risk level of systems already in use. Buyers should plan separate phases for discovery, risk classification, control design, integration, validation, and production monitoring, with clinical AI receiving more review than low-impact administrative automation.
What should healthcare providers ask AI vendors during procurement?
Ask for the exact model version, intended and prohibited uses, validation populations, known limitations, data-retention settings, subprocessors, breach-notification process, and audit-log format. Also request advance notice of model changes and confirm whether logs can be exported through REST APIs, JSON, CSV, or FHIR.
Is NIST AI RMF enough for healthcare AI governance?
NIST AI RMF provides a defined risk-management structure, but healthcare buyers generally need additional clinical validation, privacy controls, EHR workflow testing, and ONC-related documentation. FUTURE-AI principles can complement NIST by focusing attention on fairness, universality, traceability, usability, robustness, and explainability in clinical settings.
⬇️